[Predictive markers in gynaecological, prostate, and breast cancers].

The implementation of targeted therapies in oncology has brought significant improvement in the treatment of many solid tumours. At the same time, pathological and molecular pathological diagnostics became more important. Today, there are hardly any solid tumours that do not require predictive biomarker testing. In recent years, a number of new targeted therapies have emerged for gynaecological tumours, prostate and breast cancer. In this article, we summarise the molecular pathology tests required in these tumours based on current clinical and pathological guidelines.